PCIB.OL
PCI Biotech Holding ASA [PCIB.OL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PCIB.OL Stock Summary
Top 10 Correlated Stocks
PCIB.OL
In the News
PCIB.OL Financial details
Company Rating
Neutral
Market Cap
73.68M
Income
-73.45M
Revenue
0
Book val./share
1.7
Cash/share
1.8
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
09 May 2023
P/E
-0.98
Forward P/E
-
PEG
-1.21
P/S
-
P/B
1.13
P/C
1.12
P/FCF
-1.15
Quick Ratio
6.97
Current Ratio
7.52
Debt / Equity
0.16
LT Debt / Equity
0.01
-
-
EPS (TTM)
-2.1
EPS next Y
-
EPS next Q
-
EPS this Y
-56.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-25.64%
-
-
-
-
SMA20
-17.07%
SMA50
-1.92%
SMA100
10.87%
Inst Own
-
Inst Trans
-
ROA
-99%
ROE
-86%
ROC
-1.13%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
39.33M
Shs Float
28.79M
-
-
-
-
Target Price
-
52W Range
1.518-5.96
52W High
-59.6%
52W Low
+102%
RSI
41.96
Rel Volume
0.03
Avg Volume
518.21K
Volume
14.67K
Perf Week
-6.91%
Perf Month
-12.55%
Perf Quarter
20.67%
Perf Half Y
1.92%
-
-
-
-
Beta
1.9412
-
-
Volatility
0.03%, 0.22%
Prev Close
-1.22%
Price
2.02
Change
6.09%
PCIB.OL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.63 | -1.25 | -2.38 | -1.94 | -0.84 | |
| Operating cash flow per share | -1.17 | -1.12 | -2.24 | -2.08 | -0.65 | |
| Free cash flow per share | -1.17 | -1.12 | -2.24 | -2.08 | -0.65 | |
| Cash per share | 1.91 | 12.54 | 6.98 | 5.02 | 1.1 | |
| Book value per share | 1.6 | 12.23 | 6.84 | 5.08 | 1.08 | |
| Tangible book value per share | 1.6 | 12.23 | 6.84 | 5.08 | 1.08 | |
| Share holders equity per share | 1.6 | 12.23 | 6.84 | 5.08 | 1.08 | |
| Interest debt per share | 0 | 0 | 0.05 | 0.03 | 0.02 | |
| Market cap | 1.03B | 750.52M | 2.86B | 1.04B | 1.46B | |
| Enterprise value | 974.85M | 401.89M | 2.6B | 853.76M | 1.35B | |
| P/E ratio | -23.93 | -21.58 | -32.18 | -14.4 | -16.51 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -33.48 | -24.15 | -34.21 | -13.44 | -21.36 | |
| PFCF ratio | -33.48 | -24.15 | -34.21 | -13.44 | -21.36 | |
| P/B Ratio | 24.5 | 2.21 | 11.21 | 5.5 | 12.82 | |
| PTB ratio | 24.5 | 2.21 | 11.21 | 5.5 | 12.82 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -22.76 | -11.6 | -29.75 | -12.26 | -15.69 | |
| EV to operating cash flow | -31.84 | -12.93 | -31.11 | -11.03 | -19.7 | |
| EV to free cash flow | -31.84 | -12.93 | -31.11 | -11.03 | -19.7 | |
| Earnings yield | -0.04 | -0.05 | -0.03 | -0.07 | -0.06 | |
| Free cash flow yield | -0.03 | -0.04 | -0.03 | -0.07 | -0.05 | |
| Debt to equity | 0.4 | 0.05 | 0.11 | 0.11 | 0.19 | |
| Debt to assets | 0.28 | 0.05 | 0.1 | 0.1 | 0.16 | |
| Net debt to EBITDA | 1.17 | 10.06 | 2.96 | 2.68 | 1.32 | |
| Current ratio | 4.01 | 21.01 | 11.2 | 10.13 | 6.14 | |
| Interest coverage | 0 | -380.5 | -175.5 | -206.85 | -966.62 | |
| Income quality | 0.71 | 0.89 | 0.94 | 1.07 | 0.77 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.66 | 18.56 | 19.16 | 14.87 | 4.54 | |
| ROIC | 1 | 0.13 | 0.36 | 0.48 | 0.88 | |
| Return on tangible assets | -0.73 | -0.1 | -0.31 | -0.35 | -0.65 | |
| Graham Net | 1.28 | 11.93 | 6.25 | 4.49 | 0.89 | |
| Working capital | 43.83M | 340.04M | 251.12M | 181.28M | 107.41M | |
| Tangible asset value | 41.84M | 339.95M | 254.83M | 189.24M | 113.79M | |
| Net current asset value | 41.82M | 339.94M | 248.55M | 181.25M | 106.13M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.02 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.79M | 1.69M | 5.25M | 6.9M | 4.47M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.02 | -0.1 | -0.35 | -0.38 | -0.78 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.57 | -0.8 | -0.62 | -0.39 | -0.29 | |
| Operating cash flow per share | -0.35 | -0.55 | -0.58 | -0.49 | -0.24 | |
| Free cash flow per share | -0.35 | -0.55 | -0.58 | -0.49 | -0.24 | |
| Cash per share | 3.63 | 3.66 | 2.51 | 2.04 | 1.8 | |
| Book value per share | 3.65 | 3.62 | 2.38 | 2.03 | 1.7 | |
| Tangible book value per share | 3.65 | 3.62 | 2.38 | 2.03 | 1.7 | |
| Share holders equity per share | 3.65 | 3.62 | 2.38 | 2.03 | 1.7 | |
| Interest debt per share | 0.06 | -0.03 | 0.06 | 0.05 | 0.04 | |
| Market cap | 636.41M | 437.15M | 162.07M | 150.8M | 64.42M | |
| Enterprise value | 502.9M | 323.88M | 70.14M | 76.06M | -1.37M | |
| P/E ratio | -7.43 | -4.36 | -1.76 | -2.57 | -1.51 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -48.43 | -25.24 | -7.51 | -8.3 | -7.29 | |
| PFCF ratio | -48.43 | -25.24 | -7.51 | -8.3 | -7.29 | |
| P/B Ratio | 4.67 | 3.84 | 1.83 | 1.99 | 1.01 | |
| PTB ratio | 4.67 | 3.84 | 1.83 | 1.99 | 1.01 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -24.44 | -11.83 | -4.25 | -5.33 | 0.13 | |
| EV to operating cash flow | -38.27 | -18.7 | -3.25 | -4.19 | 0.15 | |
| EV to free cash flow | -38.27 | -18.7 | -3.25 | -4.19 | 0.15 | |
| Earnings yield | -0.03 | -0.06 | -0.14 | -0.1 | -0.17 | |
| Free cash flow yield | -0.02 | -0.04 | -0.13 | -0.12 | -0.14 | |
| Debt to equity | 0.14 | 0.19 | 0.23 | 0.23 | 0.16 | |
| Debt to assets | 0.12 | 0.16 | 0.19 | 0.19 | 0.14 | |
| Net debt to EBITDA | 6.49 | 4.14 | 5.58 | 5.24 | 6.3 | |
| Current ratio | 8.53 | 6.14 | 5.53 | 5.61 | 7.52 | |
| Interest coverage | -107.67 | 7.78 | -38.39 | -60.62 | -121.61 | |
| Income quality | 0.61 | 0.69 | 0.94 | 1.24 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.86 | 8.06 | 5.74 | 4.24 | 3.31 | |
| ROIC | 0.19 | 0.24 | 0.28 | 0.24 | 0.17 | |
| Return on tangible assets | -0.14 | -0.18 | -0.21 | -0.16 | -0.14 | |
| Graham Net | 3.13 | 2.96 | 1.96 | 1.58 | 1.52 | |
| Working capital | 129.27M | 107.41M | 88.19M | 75.32M | 62.87M | |
| Tangible asset value | 136.14M | 113.79M | 88.8M | 75.93M | 63.48M | |
| Net current asset value | 127.88M | 106.13M | 87.07M | 74.36M | 62.07M | |
| Invested capital | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 3.09M | 2.92M | 4.08M | 4.91M | 3.87M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.16 | -0.22 | -0.26 | -0.19 | -0.17 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
PCIB.OL Frequently Asked Questions
What is PCI Biotech Holding ASA stock symbol ?
PCI Biotech Holding ASA is a NO stock and trading under the symbol PCIB.OL
What is PCI Biotech Holding ASA stock quote today ?
PCI Biotech Holding ASA stock price is $2.02 today.
Is PCI Biotech Holding ASA stock public?
Yes, PCI Biotech Holding ASA is a publicly traded company.
Company Profile
- Volume Average 518.21K
- Market Capitalization 73.68M
- Employee 14
- CEO Mr. Ronny Skuggedal
- Headquarters Oslo,NO
- IPO Date 2008-06-23
-
Website
https://www.pcibiotech.com 
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
